Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma

Ewing sarcoma (ES) is the second most common pediatric bone cancer. Despite recent advances in treatment, patients with metastatic tumors have dismal prognosis and hence novel therapies are urgently needed to combat this A study has shown that phosphoinositide-3 kinase (PI3K) inhibitors can synergistically increase sensitivity bromodomain extraterminal domain ES cells therefore combined inhibition of PI3K proteins might provide benefit Herein, we investigated efficacy dual PI3K/BRD4 inhibitors, SF2523 SF1126, for their antitumor activity cell lines. The effect SF1126 on viability signaling was assessed a panel human To evaluate A673 were injected intrafemorally into RAG-2−/− mice treated 50 mg/kg 6 days per week, 30 days. Both decreased survival inhibited phosphorylation AKT In vivo, showed significant reduction tumor volume. These results suggest inhibitor, models.